Avalo Therapeutics AVTX
NASDAQ AVTX
$8.51 +1.35 (+18.85%)
At close: Nov 11, 2026 · 4:00 PM EST

Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Updated

Avalo Therapeutics' Liabilities from Discontinued Operations was $1.76 million in Q4 2019, down 91.7% from $21.03 million a year earlier.

Analysis

Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021) Analysis & Trends

  • In earlier years, Liabilities from Discontinued Operations was $21.03 million in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Avalo Therapeutics 386.09 Mn -587.48 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 10,000.00
Jun 30, 2021 98,000.00
Mar 31, 2021 209,000.00
Dec 31, 2019 1.76 Mn
Dec 31, 2018 21.03 Mn
API Access

Avalo Therapeutics Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=AVTX&period=max&api_key=YOUR_API_KEY